Recombinant Polypeptide scFv Domain Cancer Cell Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments, including chemotherapy, surgery, radiation therapy, hormone therapy, targeted therapy, and immunotherapy, do not provide satisfactory results, leaving cancer as a significant health risk with personal, family, social, and economic burdens, necessitating the development of a novel agent and method for effective cancer treatment.

Innovation Solution

A recombinant polypeptide comprising a bi-functional domain and a single-chain fragment variable (scFv) or peptide linked to the N-terminus of the bi-functional domain, which spans cell membranes and mediates signal transduction, specifically targeting and killing cancer cells by redirecting immune cell specificity towards tumor-associated antigens.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cancer treatments (chemotherapy, surgery, radiation therapy, hormone therapy, targeted therapy, and immunotherapy) are used, then current treatment options are available, but satisfactory treatment results are not achieved

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidnovelty of treatment approach

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent segments the treatment approach by dividing the immune cell into distinct functional components: the scFv domain for antigen recognition, the transmembrane domain for membrane anchoring, and the intracellular domain for signal transduction. This segmentation allows each component to be independently optimized and combined to create a novel therapeutic agent that overcomes the limitations of conventional treatments

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent creates a composite polypeptide structure by combining three different functional domains (scFv, transmembrane domain, and intracellular domain) into a single chimeric molecule. This composite structure integrates antigen recognition, membrane insertion, and signal transduction capabilities, resulting in a novel immunotherapy approach that achieves satisfactory treatment results where conventional methods have failed

Inventive Principle:

Principle #40Composite materials

2Reliability

If existing immunotherapy methods are used, then immune response is activated, but the specificity and effectiveness against tumor-associated antigens are insufficient

Engineering Contradiction:

Improvecancer cell targeting effectivenessVSAvoidpolypeptide structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies local quality by assigning specific functions to specific regions of the polypeptide: the scFv domain at the N-terminus provides antigen-specific binding, the transmembrane domain anchors the structure in the cell membrane, and the intracellular domain mediates signal transduction. This localized functional assignment ensures high specificity for tumor-associated antigens while maintaining structural efficiency

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent creates a multi-functional polypeptide that simultaneously performs antigen recognition (scFv), membrane anchoring (transmembrane domain), and signal transduction (intracellular domain). This universal design allows a single polypeptide structure to execute multiple critical functions, improving cancer cell targeting effectiveness without requiring separate molecular components

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The engineered immune cells expressing the recombinant polypeptide effectively target and kill cancer cells, as demonstrated by cytotoxic assays and in vivo tumor growth inhibition, offering a promising approach for treating various types of cancer.

Implementation Method 1

a single-chain fragment variable (scFv) or peptide linked to the N-terminus of the bi-functional domain... specifically targeting and killing cancer cells by redirecting immune cell specificity towards tumor-associated antigens

Methodology Applied

Scientific EffectAntigen-antibody binding:

Implementation Method 2

the bi-functional domain is capable of spanning cell membrane (i.e., serving as a transmembrane domain) and mediating signal transduction in cells (i.e., serving as an intracellular domain)

Methodology Applied

Scientific EffectSignal transduction:

Implementation Method 3

The engineered immune cells expressing the recombinant polypeptide effectively target and kill cancer cells, as demonstrated by cytotoxic assays and in vivo tumor growth inhibition

Methodology Applied

Scientific EffectCytotoxic killing:

Data Source

PatentUS20250009881A1Recombinant polypeptides, recombinant nucleic acids encoding the same, and uses thereof in treating cancers

Publication Date: 2025.01.09 REPHIMMUNE BIOTECHNOLOGY INC

AI summary

Disclosed herein are recombinant polypeptides and recombinant nucleic acids encoding the same. According to some embodiments of the present disclosure, the recombinant polypeptide comprises a first bi-functional domain, and a first single-chain fragment variable (scFv) or a peptide linked to the N-terminus of the first bi-functional domain. Optionally, the recombinant polypeptide further comprises a second scFv linked to the N-terminus of the first scFv or peptide. Also disclosed herein are methods of treating cancers by using the immune cells expressing the recombinant polypeptides.